News articles about Oxford Immunotec Global PLC (NASDAQ:OXFD) have been trending somewhat negative this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a media sentiment score of -0.08 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 71 out of 100, meaning that recent press coverage is likely to have an effect on the stock’s share price in the next several days.
Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 16.71 on Thursday. The firm’s 50 day moving average price is $15.64 and its 200-day moving average price is $14.79. Oxford Immunotec Global PLC has a 52 week low of $7.73 and a 52 week high of $17.38. The firm’s market cap is $383.09 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its earnings results on Tuesday, May 2nd. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative net margin of 25.83% and a negative return on equity of 31.48%. The company had revenue of $21.51 million during the quarter, compared to the consensus estimate of $21.17 million. On average, analysts forecast that Oxford Immunotec Global PLC will post ($1.05) EPS for the current year.
A number of equities research analysts have issued reports on the company. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Finally, BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th.
COPYRIGHT VIOLATION WARNING: “Somewhat Negative Press Coverage Likely to Impact Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock Price” was reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://baseballnewssource.com/markets/somewhat-critical-press-coverage-likely-to-impact-oxford-immunotec-global-plc-nasdaqoxfd-stock-price-updated-updated/1115039.html.
In other Oxford Immunotec Global PLC news, insider Jeff R. Schroeder sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $14.14, for a total transaction of $565,600.00. Following the completion of the transaction, the insider now owns 149,544 shares in the company, valued at $2,114,552.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Wrighton-Smith sold 32,832 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $16.58, for a total transaction of $544,354.56. Following the transaction, the chief executive officer now owns 478,106 shares of the company’s stock, valued at approximately $7,926,997.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 147,085 shares of company stock valued at $2,275,928. Corporate insiders own 7.58% of the company’s stock.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with our FREE daily email newsletter.